25
Jul
2018
Finding the ‘Middle Market’ of Biotech VC: Chris Garabedian on The Long Run Podcast
Today’s guest on The Long Run podcast is Chris Garabedian. Garabedian is best known for his controversial stint as CEO of Cambridge, Mass.-based Sarepta Therapeutics, the developer of treatments for Duchenne Muscular Dystrophy. Whatever you may think of his tenure there — and the FDA’s decision to approve eteplirsen on a slim reed of clinical trial evidence – there is... Read More
20
Jul
2018
Novartis, Merck Back Off on Prices, Rubius Leads IPO Charge, CRISPR Stocks Rattled
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jul
2018
Nine Observations on Leadership and Teamwork from Mt. Everest
Most of you have heard by now that I reached the summit of Mt. Everest, the highest mountain in the world, on May 22. Not only was this a dream come true, it was the culmination of my charity fundraising campaign, the Everest Climb to Fight Cancer. It fetched $339,000 for cancer research at the Fred Hutch, a leading center... Read More
17
Jul
2018
HotSpot Therapeutics Raises $45M to Follow in Nimbus’ Footsteps, Creating Allosteric Binders
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jul
2018
Novartis Bails on Antibiotics, Acceleron Goes 2-for-2, & Grail CEO Assembles Her Team
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jul
2018
Scientist, Executive, Teacher: Vicki Sato on The Long Run Podcast
Vicki Sato is the latest guest on The Long Run podcast. Regular listeners may recall I invited Vicki on the show back in March. We had a great conversation, or so I thought. Turns out the audio recording quality was terrible. It was a technical glitch. My fault. I’m sorry you weren’t able to hear her. Fortunately, Vicki was gracious... Read More
6
Jul
2018
Biogen Hits on Alzheimer’s Study, EpiPen Rival Gets a Lift, & Bayer Doubles Down on Broad
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
29
Jun
2018
Amazon’s Chess Move and the Pre-Holiday IPO Wave Continues
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Jun
2018
How Are Biotech VC Funds Performing? See Data From Five State Pension Funds
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
Jun
2018
How Are Biotech’s VCs Performing? Not As Well As You May Think
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
Jun
2018
Sarepta’s Stunner, Summer IPO Wave, and a White House Plan to Clip Wings at FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
21
Jun
2018
Impact in More Ways Than One: Tony Coles on The Long Run Podcast
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2018
Bluebird Gene Therapy Holding Up, CRISPR Gyrations, and a Clever Antibiotic Business Idea
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2018
EHA18 Preview: Blood Drugs to Watch in Stockholm
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2018
BIO18 Reflections, Axovant and Ophthotech Reboot with Gene Therapy & More
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Jun
2018
From Hoop Dreams to the Biopharma Big Time: Rob Perez on The Long Run
Today’s guest on the show is Rob Perez. He grew up in a lower-middle class household in Los Angeles. Had some hoop dreams that never quite materialized. No big deal. Perez found he had a knack for sales, and paid his way through college by working at fitness centers. Chance brought him into the pharmaceutical sales business. He liked meeting... Read More
23
May
2018
Re-Starting a Company, Keeping Hope Alive: Chip Clark on The Long Run
Today’s guest on The Long Run is Chip Clark. He’s the CEO of Cambridge, Mass.-based Genocea Biosciences. This vaccine platform company got into a jam last summer. It completed a Phase II trial with its lead therapeutic vaccine for genital herpes. Clark tried to insist the trial was a success and the product had a future. The market disagreed. The... Read More
9
May
2018
Charting His Own Entrepreneurial Course: Ethan Perlstein on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Apr
2018
What Can You Do With Genomics and AI? Alice Zhang on The Long Run
Today’s guest on The Long Run podcast is Alice Zhang. Let’s start with some basic background. Zhang studied systems biology at Princeton, graduated with honors, enrolled in an MD/PHD program at UCLA/Caltech, stayed there five years, quit, moved to Silicon Valley, and co-founded a company dedicated to using her knowledge for neurodegenerative drug discovery. She has been named among the... Read More
11
Apr
2018
The Immune Sequencing Frontier: Harlan and Chad Robins on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.